Investment Centers of America Inc. continued to hold its stake in Humana Inc. (NYSE:HUM) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,531 shares of the insurance provider’s stock at the end of the second quarter. Investment Centers of America Inc.’s holdings in Humana were worth $368,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Federated Investors Inc. PA raised its stake in Humana by 608.1% during the second quarter. Federated Investors Inc. PA now owns 34,626 shares of the insurance provider’s stock worth $8,331,000 after purchasing an additional 29,736 shares during the period. Creative Planning raised its stake in Humana by 0.3% during the second quarter. Creative Planning now owns 4,874 shares of the insurance provider’s stock worth $1,173,000 after purchasing an additional 15 shares during the period. Cipher Capital LP raised its stake in Humana by 7.7% during the second quarter. Cipher Capital LP now owns 9,734 shares of the insurance provider’s stock worth $2,342,000 after purchasing an additional 698 shares during the period. OZ Management LP raised its stake in Humana by 4.9% during the second quarter. OZ Management LP now owns 667,478 shares of the insurance provider’s stock worth $160,608,000 after purchasing an additional 30,927 shares during the period. Finally, US Bancorp DE increased its position in shares of Humana by 4.4% during the second quarter. US Bancorp DE now owns 44,359 shares of the insurance provider’s stock valued at $10,674,000 after acquiring an additional 1,870 shares during the last quarter. 95.12% of the stock is currently owned by institutional investors.

In other Humana news, insider William Kevin Fleming sold 3,071 shares of the stock in a transaction that occurred on Wednesday, August 23rd. The shares were sold at an average price of $250.98, for a total value of $770,759.58. Following the completion of the sale, the insider now owns 7,681 shares of the company’s stock, valued at $1,927,777.38. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Brian P. Leclaire sold 4,971 shares of the stock in a transaction that occurred on Wednesday, June 28th. The shares were sold at an average price of $240.00, for a total transaction of $1,193,040.00. Following the completion of the sale, the senior vice president now directly owns 14,258 shares of the company’s stock, valued at approximately $3,421,920. The disclosure for this sale can be found here. Insiders sold 60,566 shares of company stock valued at $15,326,746 in the last ninety days. 0.80% of the stock is owned by corporate insiders.

HUM has been the subject of a number of recent analyst reports. UBS AG reiterated a “neutral” rating and set a $250.00 price target (up from $237.00) on shares of Humana in a research report on Wednesday, August 9th. Zacks Investment Research cut shares of Humana from a “hold” rating to a “sell” rating in a research report on Thursday, July 27th. Cowen and Company reiterated a “buy” rating and set a $230.00 price target on shares of Humana in a research report on Friday, July 14th. BidaskClub upgraded shares of Humana from a “sell” rating to a “hold” rating in a research report on Thursday, August 10th. Finally, Cantor Fitzgerald reiterated a “neutral” rating and set a $223.00 price target (up from $200.00) on shares of Humana in a research report on Thursday, August 3rd. One analyst has rated the stock with a sell rating, nine have given a hold rating and thirteen have issued a buy rating to the company. Humana has a consensus rating of “Buy” and a consensus target price of $244.35.

Humana Inc. (NYSE:HUM) opened at 249.28 on Monday. The company has a 50-day moving average of $250.25 and a 200-day moving average of $231.50. Humana Inc. has a 52 week low of $163.50 and a 52 week high of $259.76. The stock has a market cap of $36.03 billion, a P/E ratio of 20.51 and a beta of 0.87.

Humana (NYSE:HUM) last posted its earnings results on Wednesday, August 2nd. The insurance provider reported $3.49 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.08 by $0.41. Humana had a net margin of 3.37% and a return on equity of 15.85%. The firm had revenue of $13.53 billion during the quarter, compared to the consensus estimate of $13.61 billion. During the same quarter in the prior year, the company earned $2.30 EPS. On average, analysts predict that Humana Inc. will post $11.55 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 27th. Shareholders of record on Tuesday, August 29th will be given a $0.40 dividend. This represents a $1.60 annualized dividend and a yield of 0.64%. The ex-dividend date is Thursday, September 28th. Humana’s dividend payout ratio (DPR) is 13.06%.

WARNING: This article was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another site, it was illegally copied and reposted in violation of US and international copyright legislation. The correct version of this article can be read at https://www.thecerbatgem.com/2017/09/18/humana-inc-hum-position-held-by-investment-centers-of-america-inc.html.

Humana Profile

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM).

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Stock Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related stocks with our FREE daily email newsletter.